Importantly, clinical trials of mutant IDH inhibitors have shown enhanced patient survival, but in most cases, this is associated with inhibition of tumor growth rather than tumor shrinkage.7–9 As a result, pretreatment information regarding tumor growth rate is required in order to assess the impact of treatment, and confirming drug action at the tumor site can be challenging. This evidence concerns the gene IDH1 and neoplasm.